Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02367014 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy
A Phase 1 study of Mitochondrial Myopathy, sponsored by Stealth BioTherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 4
- Study locations
NCT02367014 is a Phase 1 study of Mitochondrial Myopathy that has completed, run by Stealth BioTherapeutics. The registered enrollment target is 36 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT02367014, a Phase 1 study of Mitochondrial Myopathy, has completed, sponsored by Stealth BioTherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 4
- Study locations
Study Summary
Phase 1/2, multi-center, randomized, double-blind, multiple ascending dose, placebo-controlled study that enrolled 36 subjects with mitochondrial myopathy associated with genetically confirmed mitochondrial disease to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of MTP-131 in this patient population.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG elamipretide (low dose)
- DRUG elamipretide (intermediate dose)
- DRUG elamipretide (high dose)
Study Locations (4)
California
- University of California - San Diego
Massachusetts
- Massachusetts General Hospital - Boston
Ohio
- Akron Children's Hospital - Akron
Pennsylvania
- Children's Hospital of Pittsburg of UPMC - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2015-02 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02367014
The ClinicalTrials.gov registry entry for NCT02367014 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stealth BioTherapeutics, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mitochondrial Myopathy appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT02367014 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Massachusetts, Ohio.
Frequently Asked Questions
What is clinical trial NCT02367014 about?
NCT02367014 is a clinical study titled "Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy". Phase 1/2, multi-center, randomized, double-blind, multiple ascending dose, placebo-controlled study that enrolled 36 subjects with mitochondrial myopathy associated with genetically confirmed mitochondrial disease to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy...
What is the current status of trial NCT02367014?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2015-02. Estimated completion is 2016-04.
What conditions does trial NCT02367014 study?
This clinical trial studies the following conditions: Mitochondrial Myopathy.
What interventions are being tested in trial NCT02367014?
The interventions under investigation include: Placebo (DRUG), elamipretide (low dose) (DRUG), elamipretide (intermediate dose) (DRUG), elamipretide (high dose) (DRUG).
Who is sponsoring clinical trial NCT02367014?
This trial is sponsored by Stealth BioTherapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02367014 being conducted?
This trial has 4 study locations across California, Massachusetts, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mitochondrial Myopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.